Clinical trials for glaucoma neuroprotection are not impossible

Current Opinion in Ophthalmology

Volumn 23, Issue 2, 2012, Pages 144-154

  Quigley, Harry A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical trial; Glaucoma; Neuroprotection

Indexed keywords

BRIMONIDINE; TIMOLOL;

CELL SURVIVAL; CELL VIABILITY; CLINICAL TRIAL (TOPIC); CLOSED ANGLE GLAUCOMA; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PERIMETRY; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW; TRABECULECTOMY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GLAUCOMA; HUMANS; NERVE FIBERS; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS;

EID: 84857236328     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834ff490     Document Type: Review

References (48)

1. Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol 2011; 22:78-86. A review of specific issues in the study of glaucoma neuroprotectio.n.
2. Artes PH, Hutchison DM, Nicolela MT, et al. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest Ophthalmol Vis Sci 2005; 46:2451-2457. (Pubitemid 43119493)
3. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998; 126:487-497.
4. Heijl A, Leske MC, Bengtsson B, Hyman L, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268-1279. (Pubitemid 36105431)
5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-713. (Pubitemid 34620348)
6. Ramulu P. Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol 2009; 20:92-98. A review of the functional implications of glaucoma damag.e.
7. Burgoyne CF, Downs JC. Premise and prediction -how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. J Glaucoma 2008; 17:318-328.
8. Sigal IA, Ethier CR. Biomechanics of the optic nerve head. Exp Eye Res 2009; 88:799-807.
9. Costa VP, Arcieri ES, Harris A. Blood pressure and glaucoma. Br J Ophthalmol 2009; 93:1276-1282.
10. Leske MC. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr Opin Ophthalmol 2009; 20:73-78.
11. Wax MB. The case for autoimmunity in glaucoma. Exp Eye Res. 2011; 93:187-190.
12. Quigley HA. Neuronal death in glaucoma. Prog Ret Eye Res 1998; 18:39-57. (Pubitemid 28457038)
13. Baltmr A, Duggan J, Nizaria S, et al. Neuroprotection in glaucoma -is there a future role? Exp Eye Res 2010; 91:554-566.
14. Coleman AL,Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol 2008; 53 (Suppl 1):S3-S10.
15. Heijl A, Bengtsson B, Hyman L, et al. Natural history of open-angle glaucoma. Ophthalmology 2009; 116:2271-2276.
16. Caprioli J, Zeyen T. A critical discussion of the rates of progression and causes of optic nerve damage in glaucoma. J Glaucoma 2009; 18:S1-S21.
17. Broman AT, Quigley HA, West SK, et al. Estimating the rate of progressive visual field damage among those with open-angle glaucoma from crosssectional data. Invest Ophthalmol Vis Sci 2008; 49:66-76.
18. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology 2007; 114:1965-1972. (Pubitemid 350016362)
19. Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol 2009; 148:186-191.
20. Levin LA, Danesh-Meyer HV. Lost in translation: bumps in the road between bench and bedside. JAMA 2010; 303:1533-1534.
21. Chrysotomou V, Trounce IA, Crowston J. Mechanisms of retinal ganglion cell injury in aging and glaucoma. Ophthalmic Res 2010; 44:173-178.
22. Cone FE, Gelman SE, Son JL, et al. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Exp Eye Res 2010; 91:415-424.
23. Robin AL, Quigley HA, Pollack IP, et al. An analysis of visual acuity, visual fields, and disk cupping in childhood glaucoma. Am J Ophthalmol 1979; 88:847-858. (Pubitemid 10236331)
24. McKinnon SJ, Schlamp CL, Nickells RW. Mouse models of retinal ganglion cell death and glaucoma. Exp Eye Res 2009; 88:816-824.
25. Pang I-H, Clark AF. Rodent models for glaucoma retinopathy and optic neuropathy. J Glaucoma 2007; 16:483-505. (Pubitemid 47263052)
26. Cioffi GA, Wang L, Fortune B, et al. Chronic ischemia induces regional axonal damage in experimental primate optic neuropathy. Arch Ophthalmol 2004; 122:1517-1525. (Pubitemid 39336552)
27. Harada C, Namekata K, Guo X, et al. ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma. Cell Death Differ 2010; 17:1751-1759.
28. Lebrun-Julien F, DiPolo A. Molecular and cell-based approaches for neuroprotection in glaucoma. Optom Vis Sci 2008; 85:E417-E424.
29. Pease ME, Zack DJ, Berlinicke CA, et al. CNTF over-expression leads to increased retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50:2194-2200.
30. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. PNAS 2007; 104:13444-13449.
31. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey. II: Structural measures. Invest Ophthalmol Vis Sci 2004; 45:2640-2651. (Pubitemid 38998860)
32. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004; 62:455-459. (Pubitemid 38253028)
33. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol 2006; 124:520-526.
34. Zhou Y, Pernet V, Hauswirth WW, Di Polo A. Activation of the extracellular signal-regulated kinase 1/2 pathway by AAV gene transfer protects retinal ganglion cells in glaucoma. Mol Ther 2005; 12:402-412. (Pubitemid 41150125)
35. Levkovitch-Verbin H, Vander S, Melamed S. Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats. J Glaucoma. 2011; 20:273-277.
36. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing- 4 protects optic nerve axons in a rat glaucoma model. Mol Ther 2002; 5:780-787. (Pubitemid 34619071)
37. Bakalash S, Kessler A, Mizrahi T, et al. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003; 44:3374-3381. (Pubitemid 36909773)
38. Libby RT, Li Y, Savinova OV, et al. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet 2005; 1:17-26.
39. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007; 48:1212-1218. (Pubitemid 351261416)
40. Huang W, Fileta JB, Dobberfuhl A, et al. Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci 2005; 102:12242-12247. (Pubitemid 41291159)
41. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26:12633-12641. (Pubitemid 44904557)
42. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2010; (2):CD006539. doi: 10.1002/14651858.CD006539.pub2.
43. Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151:671-681.
44. Schwid SR, Cutter GR. Futility studies. Spending a little to save a lot. Neurology 2006; 66:626-627. (Pubitemid 43739812)
45. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for Parkinson disease. Using futility designs. Neurology 2006; 66:628-633. (Pubitemid 43739813)
46. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140:598-606.
47. Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2010; 92:569-573. (Pubitemid 351497993)
48. Liu MM, Tuo J, Chan C-C. Gene therapy for ocular diseases. Br J Ophthalmol 2011; 95:604-612.